Artificial intelligence is increasingly making its way into the pharmaceutical industry, and Tata Consultancy Services (TCS) has now introduced a new platform designed to bring AI agents into drug development and clinical research.

Called TCS ADD AgentHub, the platform is designed to help pharmaceutical companies use AI for tasks across drug development, clinical trials and drug safety. According to TCS, the goal is to automate repetitive work while keeping humans in control of important decisions.

What is TCS ADD AgentHub?

TCS ADD AgentHub is an agentic AI platform that allows pharmaceutical companies to build and deploy customized AI agents for specific workflows.

These AI agents can be assigned different responsibilities depending on the needs of a pharmaceutical organization. The platform is designed to work across several stages of the drug development process.

Potential applications include:

• Clinical data review

• Clinical study design

• Protocol digitization

• Research paper and document analysis

• Medical monitoring

• Drug safety case processing

By handling repetitive and data-intensive tasks, AI agents could help research and clinical teams spend more time on work that requires human expertise and judgment.

Humans will remain responsible for key decisions

One of the key aspects of the platform is TCS's "Human Plus AI" approach.

The idea is not to completely replace human teams with AI. Instead, AI agents can handle predefined and repetitive parts of a workflow, while people continue to oversee the process, manage governance and make final decisions.

This is particularly important in pharmaceutical research, where decisions involving clinical trials, patient safety and medicines require careful human oversight.

Why is AI useful in pharmaceutical research?

Drug development involves enormous amounts of information spread across different systems and sources. Clinical trial data, research documents, safety reports and other records can be difficult and time-consuming to process manually.

AI agents can potentially help organize, analyze and process this information more efficiently. Automating repetitive activities could also reduce the workload on research and clinical teams.

However, the quality of AI-generated results still depends on the underlying data, system design and human review.

TCS claims up to 40% efficiency improvement

TCS says solutions developed using AgentHub have already demonstrated efficiency improvements in certain pharmaceutical workflows.

According to the company's claims:

• Clinical data management efficiency can improve by up to 40%.

• Metadata-based automation can reduce clinical study preparation effort by up to 30%.

• End-to-end safety case processing costs can be reduced by up to 30%.

• AI-powered safety agents can reduce quality-control workload by up to 50%.

These numbers are claims made by TCS and actual results can vary depending on the organization, workflow, data and implementation.

Could AgentHub change pharma workflows?

The launch highlights how agentic AI is moving beyond general-purpose chatbots and into specialized business processes.

If implemented with appropriate safeguards, AI agents could help pharmaceutical companies automate repetitive work, process large volumes of information and potentially speed up certain stages of research and clinical operations.

At the same time, pharmaceutical workflows involve strict regulatory, safety and quality requirements. Human oversight will therefore remain important, particularly when AI-generated information could influence clinical or drug-safety decisions.

TCS's AgentHub represents another step toward combining AI automation with human expertise in one of the world's most data-intensive industries.